About Ception Therapeutics
Ception Therapeutics is a Healthcare company based in Malvern (United States) founded in 2004, and was acquired by Cephalon in February 2010. Drugs for inflammatory conditions are discovered, developed, and commercialized. Ception Therapeutics has raised $77.7 million across 2 funding rounds from investors including Cephalon, GreenLight Capital and Growth Capital Fund. Ception Therapeutics offers products and services including Payroll Outsourcing and Payroll Services. Its focus areas include Life Sciences, Immunology, Drugs and Inflammatory Diseases. Its legal entity is Ception Therapeutics, Inc. Its competitors include Aclaris Therapeutics, Escient Pharmaceuticals and MacroGenics; 3 of its 3 listed competitors have raised funding.
Company details
Ception Therapeutics was established in 2004 in Malvern, United States, within the biotechnology sector. Focus is placed on discovering, developing, and commercializing treatments for inflammatory conditions. Reslizumab, a monoclonal antibody, is targeted at eosinophilic disorders. Small-molecule Anti-TNF receptor agents, suitable for oral administration, are also pursued. Since February 2010, the entity has functioned as a subsidiary of Cephalon.
- Headquarters Malvern, United States
- Stage Acquired
- SectorsHealthcare
- Website ceptiontx.com
- Acquired by Cephalon (Feb 2010)
- Legal Name Ception Therapeutics, Inc.
Products & Services of Ception Therapeutics
Ception Therapeutics offers a comprehensive portfolio of products and services, including Payroll Outsourcing and Payroll Services.
Service for managing payroll to improve data security and efficiency
Expert solutions for wage and tax handling in businesses
Funding Insights of Ception Therapeutics
Ception Therapeutics has successfully raised a total of $77.7M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $14.7 million completed in May 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $77.7M
- Total Rounds 2
- Last Round Series C — $14.7M
- First Round $63M
(Jan 2007)
- Investors Count 5
All 2 funding rounds of Ception Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2007 | $14.7M | Series C | – | – | |
| Jan 2007 | $63M | Series C | – | – |
6 investors in total: 6 institutional.
Investors in Ception Therapeutics
Ception Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Cephalon, GreenLight Capital and Growth Capital Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| growthcapitalfund.us | ||||
Early, mid, and late-stage investments are made in science sectors. | newscienceventures.com | New York, United States | ||
A healthcare-focused investment firm supporting innovative company growth. | aperturevp.com | |||
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | ewhealthcare.com | New York, United States | ||
Investment management services are provided by GreenLight Capital. | greenlightcapital.com | New York, United States | ||
Therapeutics for central nervous system disorders, pain, and cancer | 1987 | cephalon.com | Frazer, United States |
Investor details for Ception Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ception Therapeutics
4 dated milestones of Ception Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Ception Therapeutics is founded.
- Funding First funding round of $63.0M.
- Funding Latest funding round, Series C, of $14.7M.
- Exit Acquired by Cephalon.
Competitors of Ception Therapeutics
Ception Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Aclaris Therapeutics, Escient Pharmaceuticals and MacroGenics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. |
Detailed competitors of Ception Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Ception Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ception Therapeutics
Complete news archive for Ception Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ception Therapeutics
Ception Therapeutics was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Ception Therapeutics is headquartered in Malvern, United States. It is registered at Malvern, Pennsylvania, United States.
Ception Therapeutics is a funded company, having raised a total of $77.7M across 2 funding rounds to date. The company's 1st funding round was a Series C of $63M, raised on Jan 2007.
Ception Therapeutics was established in 2004 in Malvern, United States, within the biotechnology sector. Focus is placed on discovering, developing, and commercializing treatments for inflammatory conditions. Reslizumab, a monoclonal antibody, is targeted at eosinophilic disorders. Small-molecule Anti-TNF receptor agents, suitable for oral administration, are also pursued. Since February 2010, the entity has functioned as a subsidiary of Cephalon.
Ception Therapeutics's top competitors include Escient Pharmaceuticals, MacroGenics and Aclaris Therapeutics.
Ception Therapeutics offers Payroll Outsourcing and Payroll Services.
Ception Therapeutics has 6 investors. Key investors include Cephalon, GreenLight Capital, Growth Capital Fund, New Science Ventures, and Aperture Venture Partners.
Ception Therapeutics operates through Ception Therapeutics, Inc..
Yes. Ception Therapeutics was acquired by Cephalon in February 2010.